image
Healthcare - Biotechnology - NASDAQ - IL
$ 2.02
-6.82 %
$ 23.1 M
Market Cap
-1.69
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one CLGN stock under the worst case scenario is HIDDEN Compared to the current market price of 2.02 USD, CollPlant Biotechnologies Ltd. is HIDDEN

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one CLGN stock under the base case scenario is HIDDEN Compared to the current market price of 2.02 USD, CollPlant Biotechnologies Ltd. is HIDDEN

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one CLGN stock under the best case scenario is HIDDEN Compared to the current market price of 2.02 USD, CollPlant Biotechnologies Ltd. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart CLGN

image
$5.0$5.0$4.5$4.5$4.0$4.0$3.5$3.5$3.0$3.0$2.5$2.5$2.0$2.0$1.5$1.515 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '25
FINANCIALS
515 K REVENUE
-95.30%
-17.3 M OPERATING INCOME
-129.65%
-16.6 M NET INCOME
-136.63%
-14.1 M OPERATING CASH FLOW
-410.06%
-539 K INVESTING CASH FLOW
53.37%
9 K FINANCING CASH FLOW
-99.19%
164 K REVENUE
4000.00%
-3.97 M OPERATING INCOME
12.51%
-3.88 M NET INCOME
10.36%
-3.46 M OPERATING CASH FLOW
-0.46%
-58 K INVESTING CASH FLOW
58.57%
0 FINANCING CASH FLOW
0.00%
Balance Sheet CollPlant Biotechnologies Ltd.
image
Current Assets 13.2 M
Cash & Short-Term Investments 11.9 M
Receivables 583 K
Other Current Assets 688 K
Non-Current Assets 5.53 M
Long-Term Investments 0
PP&E 5.28 M
Other Non-Current Assets 249 K
63.65 %3.12 %3.68 %28.23 %Total Assets$18.7m
Current Liabilities 2.97 M
Accounts Payable 870 K
Short-Term Debt 806 K
Other Current Liabilities 1.29 M
Non-Current Liabilities 2.28 M
Long-Term Debt 2.28 M
Other Non-Current Liabilities 0
16.59 %15.37 %24.67 %43.37 %Total Liabilities$5.2m
EFFICIENCY
Earnings Waterfall CollPlant Biotechnologies Ltd.
image
Revenue 515 K
Cost Of Revenue 1.62 M
Gross Profit -1.11 M
Operating Expenses 16.1 M
Operating Income -17.3 M
Other Expenses -642 K
Net Income -16.6 M
2m2m00(2m)(2m)(4m)(4m)(6m)(6m)(8m)(8m)(10m)(10m)(12m)(12m)(14m)(14m)(16m)(16m)(18m)(18m)515k(2m)(1m)(16m)(17m)642k(17m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
-215.53% GROSS MARGIN
-215.53%
-3349.71% OPERATING MARGIN
-3349.71%
-3225.05% NET MARGIN
-3225.05%
-123.35% ROE
-123.35%
-88.77% ROA
-88.77%
-104.26% ROIC
-104.26%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis CollPlant Biotechnologies Ltd.
image
2m2m00(2m)(2m)(4m)(4m)(6m)(6m)(8m)(8m)(10m)(10m)(12m)(12m)(14m)(14m)(16m)(16m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -16.6 M
Depreciation & Amortization 1.04 M
Capital Expenditures -483 K
Stock-Based Compensation 1.72 M
Change in Working Capital -372 K
Others -221 K
Free Cash Flow -14.6 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets CollPlant Biotechnologies Ltd.
image
Wall Street analysts predict an average 1-year price target for CLGN of $12.5 , with forecasts ranging from a low of $11 to a high of $14 .
CLGN Lowest Price Target Wall Street Target
11 USD 444.55%
CLGN Average Price Target Wall Street Target
12.5 USD 518.81%
CLGN Highest Price Target Wall Street Target
14 USD 593.07%
Price
Max Price Target
Min Price Target
Average Price Target
1414121210108866442200Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 19
6. Ownership
Insider Ownership CollPlant Biotechnologies Ltd.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
COLLPLANT BIOTECHNOLOGIES ANNOUNCES EUROPEAN PATENT ALLOWANCE SECURED FOR ITS COLLAGEN-BASED FORMULATIONS USABLE AS SOFT TISSUE FILLERS AND IMPLANTS - Further protection granted in key territory applying to the significant and growing aesthetic and reconstructive markets - REHOVOT, Israel , June 4, 2025 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived, rhCollagen for tissue regeneration and medical aesthetics, today announced that the European Patent and Trademark Office has allowed a patent application related to CollPlant's injectable fillers and regenerative breast implant candidates, being developed for the aesthetic and reconstructive procedures markets, respectively. This newly allowed patent application pertains to CollPlant's injectable soft tissue fillers as well as its organ manufacturing technology related to its regenerative breast implant pipeline currently under development. prnewswire.com - 2 weeks ago
COLLPLANT BIOTECHNOLOGIES ANNOUNCES $3.6 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET UNDER NASDAQ RULES REHOVOT, Israel , May 30, 2025 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived, rhCollagen for tissue regeneration and medical aesthetics, today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 1,200,002 of the Company's ordinary shares at a purchase price of $3.00 per share in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, the Company will issue unregistered to purchase up to 1,200,002 of the Company's ordinary shares at an exercise price of $3.00 per share. prnewswire.com - 3 weeks ago
COLLPLANT BIOTECHNOLOGIES REPORTS 2025 FIRST QUARTER FINANCIAL RESULTS AND PROVIDES A CORPORATE UPDATE - In Q1 following a development achievement, CollPlant received a $2 million payment from AbbVie – - Advancement of regenerative breast implant program continues; encouraging findings continue to be observed -  REHOVOT, Israel , May 28, 2025 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived, rhCollagen for tissue regeneration and medical aesthetics, today announced financial results for the first quarter of 2025 and provided a corporate update. Yehiel Tal, CollPlant's Chief Executive Officer commented, "While advancing our core programs, we've remained disciplined in optimizing costs and prioritizing initiatives that are designed to support a well-capitalized path forward in the best interest of our shareholders. prnewswire.com - 3 weeks ago
Real World Evidence (RWE) Oncology Market to Reach $3.51 Billion by 2035, Growing at a CAGR of 14.7% from 2025--Exclusive Report by Meticulous Research® Market Growth Driven by Increasing Demand for Real-World Evidence in Drug Development, Rising Focus on Value-Based Healthcare, Growing Cancer Incidence Globally, and Advancements in Data Analytics and AI Technologies REDDING, Calif., May 27, 2025 /PRNewswire/ -- According to a new market research report titled 'RWE Oncology Solutions Market by Component (Datasets, Consulting Services), Application (Drug Development & Approvals, Market Access & Reimbursement/Coverage Decisions, Medical Device Development & Approvals, Post-market Surveillance), End User, and Geography - Global Forecast to 2035', the RWE oncology solutions market is projected to reach $3.51 billion by 2035, up from an estimated $893 million in 2025, growing at a CAGR of 14.7% during the forecast period. The growth of this market is mainly driven by increasing demand for real-world evidence in drug development, rising focus on value-based healthcare, growing cancer incidence and prevalence globally, regulatory support for RWE in healthcare decision-making, and advancements in data analytics and AI technologies. For more comprehensive insights, download the FREE report sample: https://www.meticulousresearch.com/download-sample-report/cp_id=5276 Key Market Drivers and Trends The RWE oncology solutions market is witnessing strong growth, primarily driven by the shift towards patient-centric healthcare models and the adoption of cloud-based RWE platforms that are reshaping traditional evidence generation approaches. Integration of genomic and molecular data with real-time data collection and analysis is gaining momentum. Market expansion is further supported by the growing integration with precision medicine initiatives and the development of AI-powered analytics solutions, especially in developed markets with advanced healthcare infrastructure across pharmaceutical, regulatory, and healthcare provider domains. Latest trends in the RWE oncology solutions market include the development of comprehensive cancer datasets across the healthcare ecosystem and the industry's increasing focus on evidence-driven cancer care solutions. The market is increasingly focusing on robust, integrated platforms that merge comprehensive oncology datasets with advanced analytics capabilities to meet the demands of the rapidly evolving healthcare landscape. Growth Opportunities The market presents substantial growth opportunities in expansion in emerging markets, which offers substantial opportunities for market players looking to reach new customer bases. Another major opportunity lies in the integration with precision medicine initiatives, which enhances the accessibility of personalized cancer care. Additionally, the development of AI-powered analytics solutions and partnerships between healthcare stakeholders are generating new revenue streams for solution providers as organizations increasingly seek evidence-based alternatives to traditional healthcare decision-making methods. Get Insightful Data on Regions, Market Segments, Customer Landscape, and Top Companies (Charts, Tables, Figures and More) – https://www.meticulousresearch.com/product/rwe-oncology-market-5276 Market Challenges Despite significant growth potential, the overall RWE oncology solutions market faces challenges including data privacy and security concerns straining implementation budgets, particularly in cost-sensitive healthcare sectors. Limited interoperability between healthcare systems is creating integration barriers. Additionally, recent global disruptions have exposed vulnerabilities in data standardization processes, affecting data quality and completeness. Rapidly evolving regulatory compliance requirements across different regions are creating implementation concerns, and high implementation and maintenance costs, especially for comprehensive RWE platforms, are delaying adoption, limiting scalability in key healthcare markets. Segment Insights The global RWE oncology solutions market is segmented by component (Datasets [Disparate Datasets, Integrated Datasets], Consulting Services), application (Drug Development & Approvals, Market Access & Reimbursement/Coverage Decisions, Medical Device Development & Approvals, Post-market Surveillance, Other Applications), end user (Pharmaceutical, Biotechnology, and Medical Device Companies, Healthcare Payers, Healthcare Providers, Other End Users), and geography (North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa). Market by Component The Datasets segment is expected to account for the largest share of the overall RWE oncology solutions market in 2025, primarily driven by increasing demand for comprehensive cancer data across the healthcare ecosystem, including disparate datasets (EMR/EHR/clinical data, claims & billing data, pharmacy data, cancer registries) and integrated datasets. Their comprehensive coverage, data reliability, and broad adoption across diverse healthcare applications make them indispensable in pharmaceutical research, regulatory submissions, and healthcare decision-making. However, the Consulting Services segment is expected to grow at the fastest rate through 2035, fueled by the growing need for expertise in RWE study design, regulatory guidance, and data interpretation services. Request a customized research analysis tailored to your specific requirements: https://www.meticulousresearch.com/request-customization/cp_id=5276 Market by End User The Pharmaceutical, Biotechnology, and Medical Device Companies segment is expected to account for the largest share of the global RWE oncology solutions market in 2025, primarily due to their substantial investment in oncology R&D, regulatory requirements for post-market surveillance, and the essential requirement for real-world evidence capable of supporting drug development and regulatory submissions. However, the Healthcare Payers segment is expected to witness the highest growth rate during the forecast period, driven by increasing adoption of value-based care models, the need for cost-effectiveness evidence in coverage decisions, and increasing reliance on RWE for value-based healthcare decisions. Geographic Market Insights In 2025, North America is expected to hold the largest share of the global RWE oncology solutions market, followed by Europe, due to its advanced healthcare infrastructure, strong regulatory support for RWE, well-established pharmaceutical industry, favorable reimbursement policies, and the strong presence of prominent RWE solution providers. Additionally, high cancer incidence rates and mature data analytics capabilities contribute significantly to market dominance. However, the Asia-Pacific region, particularly China, India, and South Korea, is projected to experience the fastest growth during the forecast period. This acceleration is mainly driven by rising cancer burden, expanding healthcare infrastructure, growing pharmaceutical investments, increasing awareness about precision medicine approaches, and the region's pivotal role as a global pharmaceutical manufacturing center. Immediate Delivery Available | Buy this Research Report (Insights, Charts, Tables, Figures and More)- https://www.meticulousresearch.com/view-pricing/590 Competitive Landscape The global RWE oncology solutions market is characterized by a competitive and dynamic landscape, comprising established healthcare data analytics companies, pharmaceutical service providers, technology giants, and specialized oncology data solution providers, each adopting unique approaches to advancing RWE capabilities. Market evolution is increasingly shaped by trends such as data standardization, integration of disparate data sources, and the development of AI-powered analytics solutions designed to address regulatory compliance across different regions. Leading companies are leveraging advanced data analytics capabilities to achieve comprehensive evidence generation without compromising data quality and are incorporating enhanced security measures to meet the demands of sensitive healthcare data systems. Key players in the global RWE oncology solutions market include IQVIA Holdings Inc., Veracyte Inc., Flatiron Health Inc., IBM Corporation, Oracle Corporation, SAS Institute Inc., ICON plc, Parexel International Corporation, Syneos Health Inc., Cognizant Technology Solutions Corporation, UnitedHealth Group Incorporated, Anthem Inc., Clinigen Group plc, PerkinElmer Inc., and Tempus Labs Inc., among others. Related Reports: Real-world Evidence Solutions Market Size, Share, Forecast, & Trends Analysis by Component (Datasets [Clinical, Claims, Pharmacy], Services) Application (Market Access, Drug Development & Approvals, PMS), and End User - Global Forecast to 2031https://www.meticulousresearch.com/product/real-world-evidence-solutions-market-4954 Real-world Data (RWD) Market by Source (EMR, Claims, Pharmacy, Disease Registries), Application [Market Access, Drug Development & Approvals (Oncology, Neurology), Post Market Surveillance], End User (Pharma, Payers, Providers) - Global Forecast to 2029https://www.meticulousresearch.com/product/real-world-data-market-5297 Real-world Evidence Analytics Market by Application [Market Access & Reimbursement, Drug Development & Approval (Oncology, Neurology, Cardiovascular), Post Market Surveillance, Medical Device Development], End User (Pharma, Payer, Provider) - Global Forecast to 2029https://www.meticulousresearch.com/product/real-world-evidence-analytics-market-5306 About Meticulous Research® We are a trusted research partner for leading businesses worldwide, empowering Fortune 500 organizations and emerging enterprises with market intelligence designed to drive revenue transformation and strategic growth. Our insights reveal future growth opportunities, equipping clients with a competitive edge through a versatile suite of research solutions—including syndicated reports, custom research, and direct analyst engagement. Each year, we conduct over 300 syndicated studies and manage 60+ consulting engagements across eight major sectors and 20+ geographic markets, all to deliver targeted business insights that help our clients lead in a rapidly evolving global market. With a strong focus on problem-solving for complex business challenges, our research enables organizations to navigate change with assertion, aligning it with strategic pathways for sustainable growth. By identifying innovative and effective solutions, we empower leaders to make impactful decisions that drive operational excellence and fuel innovation. We are committed to crafting insights that enhance business performance and help our clients unlock new revenue opportunities, positioning them for long-term success in the competitive global marketplace. To find out more, visit www.meticulousresearch.com or follow us on LinkedIn. Contact:Mr. Khushal BombeMeticulous Market Research Pvt. Ltd.1267 Willis St, Ste 200 Redding,California, 96001, U.S.USA: +1-646-781-8004Europe: +44-203-868-8738APAC: +91 744-7780008Email- [email protected]Visit Our Website: https://www.meticulousresearch.com/Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-researchContent Source: https://www.meticulousresearch.com/product/rwe-oncology-market-5276 Logo: https://mma.prnewswire.com/media/1757980/5251440/Meticulous_Research_Logo_1.jpg https://www.prnewswire.com - 3 weeks ago
COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR FIRST QUARTER FINANCIAL RESULTS REHOVOT, Israel , May 14, 2025 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived, rhCollagen for tissue regeneration and medical aesthetics, today announced that it will report financial results for the first quarter on Wednesday, May 28, 2025, before the opening of the U.S. financial markets. About CollPlant CollPlant is a regenerative and aesthetic medicine company ushering in a new era of medical solutions with a focus on 3D bioprinting of tissues and organs, tissue repair and medical aesthetics. prnewswire.com - 1 month ago
CollPlant's Collink.3D® BioInks and Technologies Offer a Relevant and Timely Solution to FDA's Plan to Reduce Animal Testing in Preclinical Safety Studies CollPlant's novel rhCollagen BioInks are an available solution aligned with FDA's plan announced last week to phase out the animal testing requirement for the development of monoclonal antibody therapies and other drug candidates REHOVOT, Israel , April 15, 2025 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), or "CollPlant", a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived, rhCollagen for tissue regeneration and medical aesthetics, commented today, following the United States Food and Drug Administration (FDA)'s groundbreaking step announced last week to advance public health by replacing animal testing in the development of monoclonal antibody therapies and other drug candidates with more effective, human-relevant methods. Importantly, CollPlant's Collink.3D ®  portfolio of rhCollagen-based BioInk products can be utilized for the biofabrication of tissue-on-a-chip or organ-on-a-chip systems, which serve as alternatives to animal testing. prnewswire.com - 2 months ago
CollPlant Biotechnologies Ltd. (CLGN) Q4 2024 Earnings Call Transcript CollPlant Biotechnologies Ltd. (NASDAQ:CLGN ) Q4 2024 Earnings Conference Call March 26, 2025 10:00 AM ET Company Participants Dory Kurowski - LifeSci Advisors Yehiel Tal - CEO Eran Rotem - Deputy CEO and CFO Conference Call Participants Swayampakula Ramakanth - H.C. seekingalpha.com - 2 months ago
COLLPLANT BIOTECHNOLOGIES REPORTS 2024 FINANCIAL RESULTS AND PROVIDES A CORPORATE UPDATE CollPlant announces six-month study data from its regenerative breast implant program, which could provide a revolutionary alternative to women for aesthetic or medical purposes and aims to address a $3 billion market opportunity Recently received a $2 million development payment from AbbVie Conference call to be held today at 10:00 a.m. U.S. EDT REHOVOT, Israel , March 26, 2025 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), or "CollPlant", a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and medical aesthetics, today announced its 2024 financial results and provided a corporate update. prnewswire.com - 2 months ago
COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2024 FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS AND CONFERENCE CALL INFORMATION Conference call to be held on Wednesday, March 26, 2025 at 10:00 a.m. U.S. EST REHOVOT, Israel , March 19, 2025 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq:  CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for medical aesthetics and tissue regeneration, today announced that it will report financial results for the fourth quarter and full year of 2024 on Wednesday, March 26, 2025, before the opening of the U.S. financial markets. prnewswire.com - 3 months ago
CollPlant Expands Distribution for its VergenixSTR Product in Europe and Asia REHOVOT, Israel , Feb. 24, 2025 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), or "CollPlant", a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and medical aesthetics, today announced the expansion of its distribution channels for its Vergenix™ STR product, in Europe and Asia. VergenixSTR is based on the Company's rhCollagen technology and is intended for the treatment of tendinopathy by promoting healing and repair of tendon injuries in a variety of tendons including the elbow tendon (for treatment of "tennis elbow"), rotator cuffs, patellar tendons, the Achilles tendon, and hand tendons. prnewswire.com - 3 months ago
CollPlant Biotechnologies Provides a Corporate Update -  Additional patent granted for photocurable dermal filler-  Update on AbbVie dermal filler program and achievement of contingent payment-  Plan for cost reductions in place to extend cash runway REHOVOT, Israel , Feb. 12, 2025 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), or 'CollPlant', a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and medical aesthetics, today provided a corporate update.   Photocurable Dermal Filler Program: Additional Patent Granted CollPlant today announced it has been granted U.S. Patent No. prnewswire.com - 4 months ago
CollPlant Biotechnologies Ltd (CLGN) Q3 2024 Earnings Call Transcript CollPlant Biotechnologies Ltd (NASDAQ:CLGN ) Q3 2024 Earnings Conference Call November 27, 2024 10:00 AM ET Company Participants Dory Kurowski - LifeSci Advisors Yehiel Tal - CEO Eran Rotem - Deputy CEO and CFO Operator Greetings, and welcome to the CollPlant Biotechnologies Third Quarter 2024 Earnings Call. At this time all participants are in a listen-only mode. seekingalpha.com - 6 months ago
8. Profile Summary

CollPlant Biotechnologies Ltd. CLGN

image
COUNTRY IL
INDUSTRY Biotechnology
MARKET CAP $ 23.1 M
Dividend Yield 0.00%
Description CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, and Europe. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. The company's products include BioInks for 3D printing of tissues and organs; dermal filler and soft tissue fillers for treating wrinkles; 3D Bioprinted breast implants for regeneration of breast tissue; injectable implants to promote breast tissue regeneration; 3D bioprinted regenerative soft tissue matrix; VergenixSTR, a soft tissue repair matrix intended for the treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds. It has collaboration agreements with 3D Systems Corporation; CellInk, a BICO Group company; Advanced Regenerative Manufacturing Institute; RegenMed Development Organization; Israel's Technion Institute of Technology; AbbVie; and STEMCELL. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. CollPlant Biotechnologies Ltd. was founded in 2004 and is headquartered in Rehovot, Israel.
Contact Weizmann Science Park, Rehovot, 7670104 https://www.collplant.com
IPO Date Jan. 31, 2018
Employees 57
Officers Dr. Elana Gazal Vice President of Research & Development Ms. Hadas Dreiher Horowitz Vice President of Human Resources Mr. Oren Fahimipoor Vice President of Operations Prof. Oded Shoseyov Founder & Chief Scientist Mr. Yehiel Tal Chief Executive Officer & Director Mr. Eran Rotem CPA Deputy Chief Executive Officer & Chief Financial Officer